GDTC
CYTOMED THERA (GDTC)
NASDAQ
$1.04-$0.04 (-3.61%)
Price as of Jun 23, 2026 7:10 PM EDT
  • $11.8M
    Market Cap
  • -51.46%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
279,661
+335.51%
64,214
-89.91%
636,150
-18.91%
784,495
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
279,661
+335.51%
64,214
-89.91%
636,150
-18.91%
784,495
N/A
Sales and Marketing Expense
54,374
+128.64%
23,782
-28.60%
33,307
N/A
N/A
N/A
Research and Development Expense
-2.2M
+16.13%
-1.9M
+20.12%
-1.6M
+4.40%
-1.5M
N/A
Depreciation and Amortization Expense
371,042
+15.17%
322,164
-14.03%
374,752
-1.29%
379,667
N/A
Total Operating Expenses
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Profit
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
-20,906
+2.92%
-20,313
-60.39%
-51,282
-59.03%
-125,175
N/A
Interest Income and Expense and Net
-20,906
+2.92%
-20,313
-60.39%
-51,282
-59.03%
-125,175
N/A
Total Nonoperating Income and Expense
20,906
+2.92%
20,313
-60.39%
51,282
-59.03%
125,175
N/A
Income before Taxes
-4.0M
+58.47%
-2.5M
-38.98%
-4.1M
+31.99%
-3.1M
N/A
Income Taxes
N/A
N/A
N/A
N/A
653
-60.18%
1,640
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-4.0M
+58.47%
-2.5M
-38.98%
-4.1M
+31.99%
-3.1M
N/A
Net Income from Continuing Operations Applicable to Common
-4.0M
+58.47%
-2.5M
-38.98%
-4.1M
+31.99%
-3.1M
N/A
Basic EPS and Net Income
-0.34
+54.55%
-0.22
-43.59%
-0.39
N/A
N/A
N/A
Diluted EPS and Net Income
-0.34
+54.55%
-0.22
-43.59%
-0.39
-2.50%
-0.40
N/A
Basic Weighted Average Shares
11.6M
+0.93%
11.5M
+8.56%
10.6M
N/A
N/A
N/A
Diluted Weighted Average Shares
11.6M
+0.93%
11.5M
+8.56%
10.6M
N/A
N/A
N/A
Balance Sheet
Cash and Cash Equivalents
2.1M
-55.39%
4.7M
-24.54%
6.2M
+294.01%
1.6M
N/A
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
2.1M
-55.39%
4.7M
-24.54%
6.2M
+294.01%
1.6M
N/A
Total Current Assets
3.7M
-38.96%
6.0M
-40.57%
10.1M
+304.86%
2.5M
N/A
Accumulated Depreciation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
N/A
N/A
2.1M
-16.57%
2.5M
N/A
Total Long-Term Assets
4.3M
+6.27%
4.1M
+78.99%
2.3M
-16.87%
2.7M
N/A
Total Assets
8.0M
-20.69%
10.1M
-18.60%
12.4M
+136.63%
5.2M
N/A
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
40,847
+8.49%
37,650
+10.98%
33,926
-89.87%
334,779
N/A
Total Current Liabilities
709,169
+16.90%
606,622
-15.39%
716,943
-82.79%
4.2M
N/A
Total Long-Term Debt
409,503
-5.20%
431,960
-2.20%
441,698
-45.04%
803,606
N/A
Total Long-Term Liabilities
422,117
+1.15%
417,338
+2.35%
407,772
-14.25%
475,536
N/A
Total Liabilities
1.1M
+10.48%
1.0M
-8.96%
1.1M
-75.76%
4.6M
N/A
Retained Earnings
-18.8M
+26.81%
-14.8M
+20.41%
-12.3M
+50.41%
-8.2M
N/A
Total Stockholders Equity
N/A
N/A
N/A
N/A
11.2M
+1,817.82%
586,298
N/A
Total Shares Outstanding
11.8M
+2.50%
11.5M
+0.09%
11.5M
+36.53%
8.4M
N/A
Cash Flow
Cash from Operating Activities
-3.7M
+36.44%
-2.7M
-21.06%
-3.4M
+145.48%
-1.4M
N/A
Capital Expenditures
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Investing Activities
929,283
-17.51%
1.1M
+139.82%
-2.8M
+497.75%
-473,305
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
208,648
+421.53%
-64,892
-100.59%
10.9M
+1,027.25%
968,716
N/A
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-44.27%
+96.95%
-22.48%
-52.15%
-46.98%
N/A
N/A
N/A
Return on Equity
N/A
N/A
N/A
N/A
-69.87%
N/A
N/A
N/A
Revenue Growth
335.51%
+473.18%
-89.91%
+375.45%
-18.91%
N/A
N/A
N/A
Current Ratio
5.17
-47.78%
9.89
-29.76%
14.08
N/A
N/A
N/A
Cash Ratio
2.95
-61.84%
7.74
-10.81%
8.68
N/A
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
0.04
N/A
N/A
N/A
Debt-to-Assets Ratio
0.06
+21.03%
0.05
+21.04%
0.04
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow